ReviewRole of NF-κB in thyroid cancer
Introduction
Thyroid carcinomas mainly comprise four types of tumors: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), both of which may be summarized as differentiated thyroid carcinoma, medullary thyroid carcinoma (MTC), and undifferentiated anaplastic thyroid carcinoma (ATC). PTC, FTC and ATC derive from the thyroid follicular epithelial cells, while MTC derives from the parafollicular C-cells (Sherman, 2003). PTC is the most common malignant thyroid neoplasm in countries with sufficient iodine diets, and comprises up to 80% of all thyroid malignancies. FTC is more common in regions with insufficient iodine diets and represents approximately 10–20% of all thyroid malignancies (Fagin and Mitsiades, 2008). The overall 5–10-year survival rate of patients with PTC is about 80–95%, while that of patients with FTC is about 70–95% (Gimm, 2001). The incidence of MTC is not well known because epidemiologic studies are rare. Generally, it is believed that MTC comprises about 5–10% of all thyroid malignancies (Gimm, 2001, Sherman, 2003). ATC is one of the most aggressive human malignancies, with a very poor prognosis. Although rare, accounting for up to 1–2% of clinically recognized thyroid cancers, the overall median survival is limited to months (Smallridge et al., 2009). Unfortunately, at the time of diagnosis most of ATC patients already show local and distant metastases, so that surgery, radio-therapy, and chemo-therapy, based primarily on doxorubicin and cisplatin treatment, do not meaningfully improve survival of these patients. Consequently, there is a need for new diagnostic and therapeutic tools for the treatment of these tumors.
An emerging body of literature shows that NF-κB plays a role in thyroid cancer (Visconti et al., 1997, Ludwig et al., 2001, Russell et al., 2003, Vasudevan et al., 2004, Kato et al., 2006, Palona et al., 2006, Gombos et al., 2007, Gallel et al., 2008), especially of anaplastic type (Pacifico et al., 2004, Pacifico et al., 2007, Starenki et al., 2004a, Iannetti et al., 2008, Festa et al., 2009, Zhu et al., 2009). This is an important issue because NF-κB, and particularly the genes under its transcriptional regulation, could potentially become novel molecular targets in ATC therapy, given the ability of NF-κB to control many aspects of thyroid cancer biology. This review will focus on these aspects, in particular on the molecular mechanisms by which NF-κB exerts its role in thyroid tumors.
Section snippets
NF-κB
NF-κB is a family of transcription factors that plays a central role in the regulation of apoptosis, inflammation and immune response (Ghosh et al., 1998, Karin and Ben-Neriah, 2000, Tak and Firestein, 2001). In mammals, the NF-κB family is composed of five members: RelA(p65), RelB, c-Rel, NF-κB1 (p50 and its precursor p100), NF-κB2 (p52 and its precursor p105) (Vallabhapurapu and Karin, 2009). These proteins form homodimers and heterodimers and their activity is regulated by two major
Role of NF-κB in thyroid cancer
Several lines of evidence show that NF-κB plays a role in cancer. Its activity has been found constitutively elevated in many types of human tumors from either haematological or solid origin (Pacifico and Leonardi, 2006). The role of NF-κB in solid tumors has been well documented in several studies performed on primary tumors, and neoplastic cell lines derived from different human tissues. These studies show that the inhibition of constitutive NF-κB activity blocks the oncogenic potential of
NF-κB and apoptosis in thyroid cancer
Cancer cells have the feature to circumvent apoptosis by up-regulating and/or down-regulating a number of genes involved in the control of programmed cell death. This property allows neoplastic cells to survive beyond their normal lifespan, providing protection against hypoxia as tumor mass expands, promoting angiogenesis and invasiveness during tumor progression, and allowing tumor cells to become resistant to radio- and chemo-therapy. Thus, de-regulated apoptosis is a fundamental aspect of
NF-κB links inflammation and cancer
Inflammation is central to control our fight against pathogens, and to regulate wound healing. These are very intricate biological responses that involve complex interactions among different cell types that regulate the expression of biological mediators promoting cell chemotaxis, cell migration, and cell proliferation. If inflammation is not ordered and timely, the resulting chronic inflammation can contribute to a variety of diseases including cancer. Several lines of evidence, based on
NF-κB as therapeutic target in thyroid cancer
While differentiated PTC and FTC have generally a good prognosis after surgery and radio-iodine therapy, poorly differentiated MTC and undifferentiated ATC do not respond to neither radio-iodine treatment, nor conventional chemo- and radio-therapy. These tumors are obvious candidates for alternative therapeutic approaches, such as molecularly targeted therapy. The finding that NF-κB is one of the most important tumor-promoting machinery, prompted the search for drugs able to suppress NF-κB
Conclusions
In the last few years an enormous amount of basic and clinical observations strongly implicate NF-κB in a variety of human tumors, including thyroid cancer. The strongly de-regulated NF-κB activity in human ATC represents a novel finding in the understanding of the molecular biology of thyroid cancer, that joins to those of RET, BRAF, PPARγ, PTEN, whose role has been well established in differentiated thyroid carcinomas. The future challenge is the comprehension of the molecular mechanisms
References (75)
- et al.
Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Cell
(1993) - et al.
Increased expression of NF-kappa B subunits in human pancreatic cancer cells
J. Surg. Res.
(2004) - et al.
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways
Immunity
(2002) - et al.
Molecular pathology of thyroid cancer: diagnostic and clinical implications
Best Pract. Res. Clin. Endocrinol. Metab.
(2008) - et al.
Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma
Hum. Pathol.
(2008) - et al.
Missing pieces in the NF-kappaB puzzle
Cell
(2002) Thyroid cancer
Cancer Lett.
(2001)- et al.
The IKK/NF-kappaB activation pathway—a target for prevention and treatment of cancer
Cancer Lett.
(2004) - et al.
The hallmarks of cancer
Cell
(2000) - et al.
Shared principles in NF-kappaB signaling
Cell
(2008)
NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4
J. Biol. Chem.
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2
Immunity
Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells
Gastroenterology
Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway
J. Am. Coll. Surg.
The genomic organization of the murine Pax 8 gene and characterization of its basal promoter
Genomics.
Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas
J. Biol. Chem.
NF-kappaB in solid tumors
Biochem. Pharmacol.
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species
Cell
Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation
Cell
Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development
Immunity
Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma
Histopathology
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls
Nat. Rev. Drug Discov.
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene
Proc. Natl. Acad. Sci. U.S.A.
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls
Nat. Rev. Drug Discov.
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas
Oncogene
BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells
Nat. Immunol.
Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3
Oncogene
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer
Cancer Res.
Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling
Nature
IAPs block apoptotic events induced by caspase 8 and cytochrome c by direct inhibition of distinct caspases
EMBO J.
R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway
Int. J. Cancer
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses
Annu. Rev. Immunol.
Characterization of microarray gene expression profiles of early stage thyroid tumours
Cancer Genom. Proteomics
PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer
Oncogene
The Neutrophil Gelatinase-Associated Lipocalin (NGAL), a NF-κB regulated gene, is a survival factor for thyroid neoplastic cells
Proc. Natl. Acad. Sci. U.S.A.
FOXO3a: a novel player in thyroid carcinogenesis?
Endocr Relat Cancer
Phosphorylation meets ubiquitination: the control of NF [kappa]B activity
Annu. Rev. Immunol.
Cited by (107)
High prevalence of parvovirus B19 infection in patients with thyroid nodules: A case-control study
2022, American Journal of Otolaryngology - Head and Neck Medicine and SurgeryCitation Excerpt :Also, NF-κB plays an important role in thyroid cancer, as it regulates the proliferative and anti-apoptotic activities of thyroid cancer cells. It has been shown that the level of NF-κB is higher in PTC cells than in non-cancerous thyroid cells [17]. The expression of B19 genes in cancerous tissues causes a specific change in inflammatory genes and a change in the cell environment that eventually leads to tumor formation [18].
Thyroid cancer under the scope of emerging technologies
2022, Molecular and Cellular EndocrinologySmall activating RNA-activated NIS gene promotes <sup>131</sup>I uptake and inhibits thyroid cancer via AMPK/mTOR pathway
2022, Pathology Research and PracticeTherapeutic targets of cancer drugs: Modulation by melatonin
2021, Life SciencesCitation Excerpt :In fact, gene transcription occurs after the coupling of the phosphorylated forms of P65 and P50. Aberrant NF-κB signaling has been detected in many malignancies including thyroid, gastric, prostate and lung cancers [59–62]. It has been shown that glioma cells capable of producing more melatonin show better prognosis due to the anti-apoptotic target genes of NF-κB [63].
Thyroid autoimmune disorders and cancer
2020, Seminars in Cancer Biology